Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nadolol binding to human serum proteins.

L Patel, A Johnson, P Turner

    The Journal of Pharmacy and Pharmacology
    |June 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Defective B cell development in Snell dwarf (dw/dw) mice can be corrected by thyroxine treatment.

    Journal of immunology (Baltimore, Md. : 1950)·1996
    Same author

    The carboxyl terminus of GLUT4 contains a serine-leucine-leucine sequence that functions as a potent internalization motif in Chinese hamster ovary cells.

    The Journal of biological chemistry·1996
    Same author

    Safe feeding practices for infants and young children.

    Journal of paediatrics and child health·1996
    Same author

    Clinical associations and time of onset of cerebral white matter damage in very preterm babies.

    Archives of disease in childhood. Fetal and neonatal edition·1996
    Same author

    Frequency-specific auditory brainstem responses in adults with sensorineural hearing loss.

    Audiology : official organ of the International Society of Audiology·1996
    Same author

    Gun acquisition and use by juvenile offenders.

    JAMA·1996

    Nadolol protein binding in healthy individuals ranged from 4-27%, averaging 14%. While a slight correlation with alpha-1-acid glycoprotein was noted, clinical effects from protein binding variations are improbable.

    Area of Science:

    • Pharmacology
    • Biochemistry
    • Clinical Chemistry

    Background:

    • Understanding drug protein binding is crucial for predicting pharmacokinetics and pharmacodynamics.
    • Nadolol, a beta-adrenergic blocker, exhibits variable protein binding.
    • Serum protein concentrations, particularly alpha-1-acid glycoprotein, can influence drug binding.

    Purpose of the Study:

    • To quantify the extent of nadolol protein binding in a cohort of healthy subjects.
    • To investigate the relationship between nadolol binding and serum alpha-1-acid glycoprotein levels.
    • To assess the potential clinical significance of variations in nadolol protein binding.

    Main Methods:

    • Serum samples were collected from 95 healthy individuals.
    • Nadolol protein binding was determined using established laboratory assays.

    Related Experiment Videos

  • Serum concentrations of alpha-1-acid glycoprotein were measured.

    • Main Results:

    • Nadolol protein binding varied significantly, ranging from 4% to 27%.
    • The mean protein binding of nadolol was 14% (± 4% s.d.).
    • A statistically significant, albeit small, positive correlation was observed between nadolol binding and serum alpha-1-acid glycoprotein concentration.

    Conclusions:

    • Serum protein binding of nadolol exhibits considerable inter-individual variability.
    • Alpha-1-acid glycoprotein is a minor determinant of nadolol protein binding in healthy subjects.
    • Observed variations in nadolol protein binding are unlikely to cause adverse clinical outcomes.